Table 2.

LAT expression in tumors

	LAT1(SLC7A5)		LAT2(SLC7A8)		LAT3(SLC43A1)		LAT4(SLC43A2)		4F2hc(SLC3A2)
Cancer	REF	ONC	REF	ONC	REF	ONC	REF	ONC	REF	ONC
Bladder	[92-94]	2/12
Brain/CNS	[30,42]									3/35
Breast	[34,77,95-97]	15/52		10/50				1/45	[34]	1/53
Cervical	[98]
Cholangiocarcinoma	[66]
Colorectal	[34]	23/34		4/34		2/34	[99]		[34]	6/37
Esophageal	[100]					3/9		1/6		1/9
Gastric	[36]	1/23
Head and Neck	[34,42,99,101]	7/32		2/32			[99]		[34]	3/32
Kidney		1/24				1/20		1/10		1/24
Leukemia	[87,102]	4/28		4/27	[103]					2/31
Liver	[102,104-107]				[108]				[33]
Lung	[26,35,37,67]	14/31							[37,67]
Lymphoma		8/30		1/29				2/21
Melanoma	[15,109]	3/7		1/7						1/7
Myeloma	[110-112]	1/8	[110]
Ovarian	[113,114]	3/14
Pancreatic	[32,115,116]
Pleural mesothelioma	[28]
Prostate	[24,25,39]			1/20	[17,18,24,25]	4/20				1/21
Sarcoma	[34,42]	1/20							[34]
Tongue cancer	[31]								[31]
Thymic carcinomas	[29]
Urinary tract	[92,117]
Uterine leiomyoma	[118]		[79]						[79]
Other (seminoma)						3/3
Other (skin)		4/4		4/4						1/4
Other (parathyroid)				3/3

Expression of LAT family members in a variety of cancers was assessed using Pubmed to find published references (REF) and Oncomine (ONC) to detect significant upregulation (P < 0.05, fold change > 2) for each transporter. Oncomine numbers represent Datasets with Significant Upregulation/Total Number of Datasets.